Can-Fite Biopharma Ltd (CANF) vs Evogene Ltd. (EVGN)

Can-Fite Biopharma Ltd and Evogene Ltd. are both Biotechnology companies. Can-Fite Biopharma Ltd and Evogene Ltd. are of similar size ($6.5M and $6.3M). Can-Fite Biopharma Ltd grew revenue faster over the last twelve months: −3.36% against −54.7%. Evogene Ltd. has the higher net margin (−547.6% vs −1,148.6%) and the higher return on invested capital (0.00% vs 0.00%). Across the 16 metrics below, Can-Fite Biopharma Ltd leads on 9 and Evogene Ltd. on 7.

Valuation

Metric CANF EVGN Biotechnology median
P/E n/m n/m 7.88
P/S 12.74 3.09 11.47
P/B 2.03 0.89 2.52
Price to free cash flow n/m n/m 21.16
EV/EBITDA n/m 0.39 0.74
EV/Sales 3.65 (2.55) 10.73
Earnings yield (596.58%) (216.67%) (28.84%)
Free cash flow yield (193.97%) (210.40%) (23.03%)

Profitability

Metric CANF EVGN Biotechnology median
Gross margin 0.00% (67.59%) 65.16%
Operating margin 0.00% (851.42%) 0.00%
Net margin (1,148.62%) (547.62%) 0.00%
Free cash flow margin 0.00% (650.63%) 0.00%
Return on equity 0.00% (100.03%) (57.72%)
Return on assets 0.00% (38.31%) (49.22%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric CANF EVGN Biotechnology median
Revenue growth (TTM) (3.36%) (54.71%) 5.64%
EPS growth (last fiscal year) 45.23% 62.63% —
Revenue growth, 5-year CAGR (11.90%) 29.94% 8.40%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric CANF EVGN Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 3.60 3.57 4.73
Net debt to EBITDA 0.86 1.12 0.96

Dividend

Metric CANF EVGN Biotechnology median
Dividend yield — — 2.10%
Payout ratio 0.00 0.00 0.00

Size

Metric CANF EVGN Biotechnology median
Market cap 6.54m 6.32m 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack